BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 32350373)

  • 1. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
    García-Guerrero E; Götz R; Doose S; Sauer M; Rodríguez-Gil A; Nerreter T; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Danhof S
    Leukemia; 2021 Jan; 35(1):201-214. PubMed ID: 32350373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.
    García-Guerrero E; Gogishvili T; Danhof S; Schreder M; Pallaud C; Pérez-Simón JA; Einsele H; Hudecek M
    Blood; 2017 Jun; 129(25):3386-3388. PubMed ID: 28476749
    [No Abstract]   [Full Text] [Related]  

  • 3. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
    Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
    J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
    Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
    Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
    Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
    Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.
    Bat-Erdene A; Nakamura S; Oda A; Iwasa M; Teramachi J; Ashtar M; Harada T; Miki H; Tenshin H; Hiasa M; Fujii S; Sogabe K; Oura M; Udaka K; Kagawa K; Yoshida S; Aihara KI; Kurahashi K; Endo I; Abe M
    Br J Haematol; 2019 Jun; 185(5):969-974. PubMed ID: 30474853
    [No Abstract]   [Full Text] [Related]  

  • 9. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
    Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
    Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
    Krejcik J; Frerichs KA; Nijhof IS; van Kessel B; van Velzen JF; Bloem AC; Broekmans MEC; Zweegman S; van Meerloo J; Musters RJP; Poddighe PJ; Groen RWJ; Chiu C; Plesner T; Lokhorst HM; Sasser AK; Mutis T; van de Donk NWCJ
    Clin Cancer Res; 2017 Dec; 23(24):7498-7511. PubMed ID: 29025767
    [No Abstract]   [Full Text] [Related]  

  • 13. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
    Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
    Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
    Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
    [No Abstract]   [Full Text] [Related]  

  • 15. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
    Cho N; Ko S; Shokeen M
    Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity.
    Carew JS; Espitia CM; Zhao W; Visconte V; Anwer F; Kelly KR; Nawrocki ST
    Blood Adv; 2019 Apr; 3(8):1318-1329. PubMed ID: 31015208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CD38
    Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
    Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
    Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
    Front Immunol; 2020; 11():590072. PubMed ID: 33329575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
    Lee DH; Kim GW; Kwon SH
    Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
    Ogiya D; Liu J; Ohguchi H; Kurata K; Samur MK; Tai YT; Adamia S; Ando K; Hideshima T; Anderson KC
    Blood; 2020 Nov; 136(20):2334-2345. PubMed ID: 32844992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.